XML 80 R69.htm IDEA: XBRL DOCUMENT v3.25.3
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 05, 2025
Jul. 03, 2025
Jun. 03, 2025
Jul. 02, 2024
Jul. 24, 2025
Jan. 23, 2024
Nov. 21, 2023
Jun. 25, 2022
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Oct. 31, 2024
Jul. 31, 2024
Stock based compensation                 $ 0 $ 0 $ 106,636 $ 326,525    
Payment of additional tax                     99,644      
Awarded shares       240,000                    
Research and development costs                     22,966      
Patent-related expenses                     $ 34,307      
Additional stock consideration       $ 264,000     $ 501,600              
Settelment amount                         $ 37,993 $ 37,880
Purchase price           $ 637,080                
Complementary compensation Shares                     440,000      
General and administrative expenses [Member] | National Medicines Agency [Member]                            
Stock based compensation                 $ 288,110 $ 231,750 $ 533,420 $ 463,500    
Research and development costs                     50,052      
consulting agreement [Member]                            
Stock based compensation                     68,550      
Equity issued in settlement of liabilities     $ 70,000                      
Issuance of common stock     150,000                      
Marketing Services Agreement [Member]                            
Stock based compensation $ 194,700       $ 100,000                  
Issuance of common stock 300,000       169,549                  
Fair value per share $ 0.649       $ 0.5898                  
Common stock vesting shares 150,000       28,258                  
New Consulting Agreement [Member]                            
Stock based compensation   $ 94,536                        
Issuance of common stock   240,000                        
Fair value per share   $ 0.3939                        
Common stock vesting shares   20,000                        
Phase 1 [Member]                            
Project cost               $ 838,450            
Phase 2 [Member]                            
Project cost               $ 907,084            
Four Third Party Consultants [Member]                            
Awarded shares             970,000              
Awarded share value             $ 999,100              
Cana Laboratories [Member]                            
Stock based compensation                     $ 83,719